

****Published December 2012****

MarketVIEW: West Nile Virus (WNV) vaccines (CAT: VAMV039)

Product Name	:	MarketVIEW: West Nile Virus (WNV) vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + forecast model
Therapeutic Area	:	Novel vaccines
Publication date	:	December 2012
Catalogue No	:	VAMV039

Background

West Nile Virus (WNV) is a mosquito-borne zoonotic arbovirus potentially endemic to around 83 countries worldwide including the USA, Canada and parts of Europe. WNV infections in humans are mainly asymptomatic. Clinical disease ranges from a mild febrile illness to severe encephalitis (neuroinvasive disease) which occurs in approximately 1 in 150 people infected. In the US between 1999-2009 WNV has caused 29,606 clinical cases and 1,423 deaths (CDC Figures). Due to high attention in the media, especially during the summer of 2012 there are many calls for the further development of a WNV preventative vaccine.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of West Nile Virus (WNV) vaccines across major Western markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for LO/BASE/Hi uptake scenarios per target age group(s). The product also includes an up-to-date review of latest competitor activity in the field and West Nile Virus (WNV) epidemiology in the US/Canada and other major WNV endemic countries.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to two major West Nile Virus (WNV) disease indications that could be addressed by a putative vaccine approach (RVVC and ICU). Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of nosocomial pathogens has also been utilised.

PRODUCT CONTENTS:

Published December 2012 (CAT No: VAMV039)

****This product is composed of a model and summary presentation

Contents

- Author's note
- Executive Summary
- Commercial model – key outputs
- WNV vaccine: available market (\$ 000s) to 2030 (all scenarios)
- WNV vaccine: available volume (Doses 000s) to 2030 (all scenarios)
- WNV vaccine: available market (\$ 000s) 18-49 yrs (lo scenario)
- WNV vaccine: available market (\$ 000s) >50 yrs (lo scenario)
- WNV vaccine: available market (\$ 000s) 18-49 yrs (base scenario)
- WNV vaccine: available market (\$ 000s) >50 yrs (base scenario)
- WNV vaccine: available market (\$ 000s) (other countries)
- West Nile Virus: Disease background
- West Nile Virus: introduction
- West Nile Virus: clinical description (humans)
- West Nile Virus: severe disease
- West Nile Virus: morbidity and mortality
- West Nile Virus: current treatment and management
- West Nile Virus: prevention
- West Nile Virus: epidemiology
- West Nile Virus: etiology
- West Nile Virus: hosts and mosquito species
- West Nile Virus: global distribution
- West Nile Virus: global spread and dynamics
- West Nile Virus: outbreaks 1937-2006
- West Nile Virus: US epidemiology
- West Nile Virus: US number of WNV cases/fatalities 1999-2012
- West Nile Virus: US total number by state (2008-2012)
- West Nile Virus: US Epidemiology 2012
- West Nile Virus: Texas by Age Group and Diagnosis 2012
- West Nile Virus: Epidemiology – Canada
- West Nile Virus: Epidemiology - Canada (2002 to 2007)
- West Nile Virus: Epidemiology - Canada (2007 to 2012)
- West Nile Virus: Epidemiology - Canada (2012 season)
- West Nile Virus: Epidemiology – Europe
- West Nile Virus: Europe - reported cases 2006-2009

West Nile Virus: Europe - reported cases 2010-2012
West Nile Virus: Europe - affected areas 2012
West Nile Virus: Epidemiology – Russia
West Nile Virus: Epidemiology - Latin America
West Nile Virus: Latin America - hypotheses for low WNV impact
West Nile Virus: Epidemiology – India
West Nile Virus: Epidemiology – China
West Nile Virus: Epidemiology – Australia
West Nile Virus: Epidemiology - major nations (Asia)
West Nile Virus: Summary of vaccine development
Background to West Nile Virus vaccines
West Nile vaccines: mechanism of action
West Nile vaccines: major approaches to date
Focus on ChimeriVaxTM-WN: preclinical data
Focus on ChimeriVaxTM-WN: development timeframe
Focus on ChimeriVaxTM-WN: clinical data (Phase I)
Focus on ChimeriVaxTM-WN: clinical data (Phase II)
Live-attenuated West Nile Virus vaccines: safety considerations
West Nile Virus vaccines: development challenges
West Nile Virus vaccines: regulatory issues
R&D Pipeline summary
West Nile Virus vaccine: modelling commercial potential
West Nile Virus vaccines: modeling rationale
West Nile Virus vaccines: modelling scenarios
West Nile Virus vaccines: modelling methodology
WNV vaccine: modelled target product profile (TPP)
Model assumptions: - (LO SCENARIO)
Model assumptions: - (BASE SCENARIO)
Model assumptions: - (HI SCENARIO)
West Nile vaccine: cost effectiveness/pricing
Model assumptions: WNV vaccine prices
West Nile vaccine: marketing factors
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title
Scenarios definition
CHARTS (scenarios)
CHARTS (LO)
CHARTS (BASE)
CHARTS (other countries)
Val vol summary (LO)
Val vol summary (BASE)
Val vol summary (HI)
LO SCENARIO
US 18-49 yrs (high risk states)
US >50 yrs (high risk states)



BASE SCENARIO

US 18-49 yrs (all states)

US >50 yrs (all states)

HI SCENARIO

US 18-49 yrs (other country 1)

US >50 yrs (other country 1)

US 18-49 yrs (other country 2)

US >50 yrs (other country 2)

US 18-49 yrs (other country 3)

US >50 yrs (other country 3)

US 18-49 yrs (other country 4)

US >50 yrs (other country 4)

US 18-49 yrs (other country 5)

US >50 yrs (other country 5)

US 18-49 yrs (other country 6)

US >50 yrs (other country 6)

Source data

US Arbonet (all)

US Arbonet (state by state)

US State rankings

Europe

Populations

US State populations

EU risk provinces

Back page

Worksheets = >50 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$8995.00/ GBP £5800.00[#] (Region license)*

*A region is North America, Europe or ROW


For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. US Centers For Disease Control and Prevention. Division of Vector Borne Diseases. West Nile Virus Home Page. Available at: <http://www.cdc.gov/ncidod/dvbid/westnile/index.htm>. Accessed September 2012
2. US Centers For Disease Control and Prevention. Information and Guidance For Clinicians. Available at: <http://www.cdc.gov/ncidod/dvbid/westnile/clinicians/pdf/wnv-clinicaldescription.pdf>. Accessed September 2012
3. West Nile Virus. The Center For Food Security & Public Health. Iowa State University. Available at: http://www.cfsph.iastate.edu/Factsheets/pdfs/west_nile_fever.pdf. Accessed September 2012
4. Reiter P. West Nile virus in Europe: understanding the present to gauge the future. *Euro Surveill*. 2010; 15(10); pii=19508
5. Gubler DJ et al. The continuing spread of West Nile Virus in the Western Hemisphere. *Emerging Infections (CID)* 2007;45
6. Salinas Jess D. West Nile Virus. *Emedicine/Medscape*. Available at: <http://emedicine.medscape.com/article/312210-overview> Accessed September 2012
7. Gideon. Case of the Month. "West Nile Fever" – Staying in real time. Available at: <http://www.gideononline.com/cases/westnilefever/>. Accessed September 2012
8. Artsob H et al. West Nile Virus in the New World: Trends in the Spread and Proliferation of the West Nile Virus in the Western Hemisphere
9. Asnis DS, Conetta R, Texiera AA, et al. The West Nile virus outbreak of 1999 in New York: the Flushing Hospital experience. *Clin Infect Dis* **2000**; **30**:413–8
10. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. *N Engl J Med* **2001**; **344**:1807–14.
11. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. *Ann Rev Med* **2006**; **57**:181–94.
12. US Centers of Disease Control & Prevention. West Nile virus (WMV) activity reported to ArboNET, by state 2012 and Archives. Available at: <http://www.cdc.gov/ncidod/dvbid/westnile/Mapsactivity/surv&control12MapsAnybyState.htm>. Accessed September 2012
13. Texas Department of State Health Services. West Nile virus (WMV) as of September 4, 2012. Available at: <http://www.dshs.state.tx.us/idcu/disease/arboviral/westNile/rates/>. Accessed September 2012
14. Public Health Agency of Canada. Archive: West Nile Virus (Monitor) Available at: http://www.phac-aspc.gc.ca/wnv-vwn/mon-hmnsurv-archive-eng.php#a2002_07. Accessed September 2012
15. West Nile Virus, National Surveillance Report. August 19 to August 25, 2012 (Week 34). Available at: http://www.phac-aspc.gc.ca/wnv-vwn/nsr-rms_2012/w34/index-eng.php. Accessed September 2012
16. West Nile Virus, National Surveillance Report. Available at: http://www.phac-aspc.gc.ca/wnv-vwn/nsr-rms_2012/w34/index-eng.php. Accessed September 2012
17. European Centre for Disease Control and Prevention. West Nile Fever. EU case definition. Available at: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/basic_facts/Pages/EU-case-definition.aspx Accessed September 2012
18. European Centre for Disease Control and Prevention. Annual Epidemiological Report on Communicable Diseases in Europe. Available at: http://ecdc.europa.eu/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf. Accessed September 2012
19. European Centre for Disease Control and Prevention. West Nile Fever. Available at: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/index.aspx Accessed September 2012
20. Platonov AE et al. Outbreak of West Nile Virus infection. Volgograd Region, Russia, 1999. *Emerg Infect Dis*. 2001; 7(1): 128-32
21. Ternovoi VA et al 2006 . The genotyping of the West Nile virus in birds in the far eastern region of Russia in 2002–2004 . *Mol Gen Mikrobiol Virusol* 4: 30 – 35
22. Pauvolid-Correa A et al. Neutralising antibodies for West Nile virus in horses from Brazilian Pantanal. *Mem Inst Oswaldo Cruz*. 2011 Jun; 106(4): 467-74
23. Petersen LR et al. West Nile Virus in the Americas. *Med Clin N Am* 92 (2008)
24. Banker DD. Preliminary observations on antibody patterns against certain viruses among inhabitants of Bombay city. *Indian J Med Sci*. 1952;6:733–46.
25. Paramasivan R, Mishra AC, Mourya DT. West Nile virus: the Indian scenario. *Indian J Med Res*. 2003;118:101–8.
26. Bondre VP et al. West Nile virus isolates from India. Evidence of a distinct genetic lineage. *J Gen Virol* (2007), 88, 875-884
27. George S et al. Isolation of Japanese Encephalitis and West Nile Viruses from fatal cases of encephalitis in Kolar district of Karnataka. *Indian J Med Res*. 1987

28. Blitvich JB. Transmission dynamics and changing epidemiology of West Nile virus. *Animal Health Research reviews*, 2008. Cambridge University Press
29. Shukla J et al. Molecular detection and characterization of West Nile Virus associated with multifocal retinitis in patients from Southern India. *Int J Infect Dis* 2012. Vol 16 (1): p 53-59
30. Lan DL et al. Serological investigations on West Nile virus in birds and horses in Shanghai, China. *Epidemiology and Infection*. FirstView Article September 2012 , pp 1-5 DOI: <http://dx.doi.org/10.1017/S0950268812001094> (About DOI), Published online: 01 June 2012
31. China Daily Website article. August 2012. Shanghai boost quarantine measures against West Nile Virus. Available at: http://www.chinadaily.com.cn/china/2012-08/28/content_15713920.htm. Accessed September 2012
32. Australian Government. Department of Health and Aging. West Nile Virus. Available at: http://www.health.gov.au/internet/main/publishing.nsf/content/cda-surveil-nndss-casedefs-cd_kunjin.htm. Accessed September 2012
33. Australian Government. Department of Health and Aging. West Nile Virus. Available at: http://www9.health.gov.au/cda/source/Rpt_3_sel.cfm. Accessed September 2012
34. Mackenzie JS, Lindsay MD, Coelen RJ, Broom AK, Hall RA, Smith DW. Arboviruses causing human disease in the Australasian zoogeographic region. *Arch Virol*. 1994;136:447-67. DOI
35. Russell RC, Dwyer DE. Arboviruses associated with human disease in Australia. *Microbes Infect*. 2000;2:1693-704.
36. Frost M et al. Characterization of Virulent West Nile Virus Kunjin Strain, Australia, 2011. *Emerg Infect Dis* (2012) Vol 18, No 5
37. Shirafuji H et al. Nationwide Surveillance of West Nile Virus Targetting Mosquitoes and Dead birds from April 2004 through March 2007 in Japan. *Zoonoses and Public Health*. Vol 58; 3 p 153-157
38. Yeh JY et al. Surveillance for West Nile Virus in Dead Wild Birds, South Korea 2005-2008. *Emerg Infect Dis*. 2011 Feb; 17(2): 299-301
39. Changbunjong T et al. Mosquito distribution and West Nile virus infection in zoos and in important sites of migratory and resident birds, Thailand. *Asian Pacific Journal of Tropical Disease*. Vol 2 Issue 4, August 2012
40. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. *Emerg Infect Dis* 2002; 8:1392-7.
41. Pierson TC et al. Structural insights into the mechanisms of antibody mediated neutralization of flavivirus infection: implications for vaccine development. *Cell Host Microbe* 2008; 4(3): 229-38
42. Monath TP et al. A live, attenuated recombinant West Nile virus vaccine. *PNAS* 103; 71 April 25th 2006. PP 6694-6699
43. Ledgerwood JE et al. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Health Adults in Phase I Clinical Trial. *J Infect Dis*. 2011.
44. Sophn G et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. *Virology Journal* 2010, 7:146
45. McDonald WF et al. A West Nile Virus Recombinant Protein Vaccine that Coactivates Innate and Adaptive Immunity. *JID* 2007;195 : 1607-17
46. Arroyo J et al. ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy (2004) *J Virol* 78, 12497-12507
47. Tesh RB et al. Efficacy of killed virus vaccine, and passive immunization for prevention of West Nile Virus encephalitis in hamster model. (2002) *Emerg Inf Dis* 8, 1392-1397
48. Johnson BW et al. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in *Aedes* and *Culex* mosquitoes. (2003). *Med Vet Entomol*. 17, 235-243
49. Monath TP et al. A live attenuated recombinant West Nile virus vaccine. *Proc Natl Acad Sci USA* 2006; 103(17):6694-6699
50. Biedenbender R et al. Phase II, Randomized, Double-Blind, Placebo controlled, Multicenter Study to Investigate the Immunogenicity and Safety of a West Nile Virus Vaccine in Healthy Adults. *J Infect Dis*. 2011; 203: 75-84
51. Sanofi Pasteur R&D Portfolio. As of February 2012. Available at: http://www.sanofipasteur.com/?codePage=PAG_22_1288245984593&codeRubrique=22. Accessed October 2012
52. FDA: New Drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human studies are not ethical Or feasible. *Federal Register* 2002, 67: 37988-37998
53. VacZine Analytics. Vaccine Pipeline Review, published December 2012 (CAT No: VAVS016)
54. Hawaii Biotech. Vaccine Technology - West Nile Virus Available at: <http://www.hibiotech.com/tech/index.html>. Accessed September 2012
55. MacroGenics Corporate Press Release. July 13 2010. Available at: <http://www.prnewswire.com/news-releases/macrogenics-announces-the-initiation-of-a-phase-2-clinical-trial-to-evaluate-the-safety-and-efficacy-of-mono-clonal-antibody-mgawn1-in-subjects-with-suspected-central-nervous-system-infection-due-to-west-nile-virus-62178912.html>. Accessed Oct 2010
56. By calculation from US Census Bureau. International Database (IDB). Available at: <http://www.census.gov/ipc/www/idb/index.php>. Accessed October 2012

57. US Centres for Disease Control and Prevention. Death rates by 10 year age groups: United States and each state, 2007. Available at: http://www.cdc.gov/nchs/data/dvs/MortFinal2007_Worktable23r.pdf. Accessed November 2012
58. Zohrabian A et al. Cost effectiveness of West Nile Virus Vaccination. Emer Inf Dis. Vol 122, No 3, March 2006

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009